Nine Lives: Alcon’s Pataday Brochure Draws Yet Another FDA Letter
This article was originally published in The Pink Sheet Daily
FDA’s most recent advertising letter to Alcon about its marketing practices makes the ninth such letter sent to the ophthalmology-focused firm in roughly 10 years; this time, the Office of Prescription Drug Promotion says the Novartis unit has omitted material facts and overstated efficacy and superiority in a brochure for Pataday.
You may also be interested in...
The eighth enforcement letter from FDA in a decade cites the company for unjustified claims about its seasonal allergic rhinitis drug, Patanase.
Promotion is not a reminder ad since the ophthalmic’s indication is depicted graphically, a notice of violation letter contends. Citation about advertising and promotional infractions is the second in about a year for Alcon Research.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.